Currently, HHT is the only ribosome inhibitor specifically used for the treatment of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS)5. This evidence concerns the gene ACVRL1 and acute myeloid leukemia.